September 2025
1. WHITE RJ, Roto D, Lachant D
   Letter by White et al Regarding Article, "Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial".
   Circulation. 2025;152:e269-e270.
   

   >> Share

   
   
2. JABER WA, Gonsalves CF, Stortecky S, Giri J, et al
   Response by Jaber et al to Letter Regarding Article, "Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial".
   Circulation. 2025;152:e271-e272.
   

   >> Share

   
   
3. JI L, Zhang H
   Letter by Ji and Zhang Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
   Circulation. 2025;152:e90-e91.
   

   >> Share

   
   
4. HE Z, Wang C, Tian H
   Letter by He et al Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
   Circulation. 2025;152:e88.
   

   >> Share

   
   
5. LIU G, Fu C, Xie J
   Letter by Liu et al Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
   Circulation. 2025;152:e92-e93.
   

   >> Share

   
   
6. SANTINI P, Pola R
   Letter by Santini and Pola Regarding Article, "Rivaroxaban for 18 Months versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
   Circulation. 2025;152:e89.
   

   >> Share

   
   
7. YAMASHITA Y, Morimoto T, Kimura T
   Response by Yamashita et al to Letter Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
   Circulation. 2025;152:e94-e95.
   

   >> Share

   
   March 2025
8. TAKAHASHI EA, Sista AK, Addison D, Bikdeli B, et al
   Disparities in Current Pulmonary Embolism Management and Outcomes: A Scientific Statement From the American Heart Association.
   Circulation. 2025 Mar 20. doi: 10.1161/CIR.0000000000001306.
   

   >> Share

   
   February 2025
9. RAO SV, Gutierrez JAT
   A Win for Clinical Evidence: The First Head-to-Head Trial of Interventional Strategies for the Treatment of Pulmonary Embolism.
   Circulation. 2025;151:274-276.
   

   >> Share

   
   November 2024
10. YAMASHITA Y, Morimoto T, Muraoka N, Shioyama W, et al
    Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).
    Circulation. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072758.
    

    >> Share

    
    October 2024
11. JABER WA, Gonsalves CF, Stortecky S, Horr S, et al
    Large-bore Mechanical Thrombectomy Versus Catheter-directed Thrombolysis in the Management of Intermediate-risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial.
    Circulation. 2024 Oct 29. doi: 10.1161/CIRCULATIONAHA.124.072364.
    

    >> Share

    
    
12. DELCROIX M, Pepke-Zaba J, D'Armini AM, Fadel E, et al
    Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy.
    Circulation. 2024;150:1354-1365.
    

    >> Share

    
    September 2024
13. ROSENFIELD K, Bowers TR, Barnett CF, Davis GA, et al
    Standardized Data Elements for Patients With Acute Pulmonary Embolism: A Consensus Report from the Pulmonary Embolism Research Collaborative.
    Circulation. 2024 Sep 12. doi: 10.1161/CIRCULATIONAHA.124.067482.
    

    >> Share

    
    
14. SINGH S, Kumar P, Padwad YS, Jaffer FA, et al
    Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach.
    Circulation. 2024;150:884-898.
    

    >> Share

    
    June 2024
15. 
    Correction to: Status and Future Directions for Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease With and Without Pulmonary Hypertension: A Scientific Statement From the American Heart Association.
    Circulation. 2024;149:e1412.
    

    >> Share

    
    March 2024
16. AGGARWAL V, Giri J, Visovatti SH, Mahmud E, et al
    Status and Future Directions for Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease With and Without Pulmonary Hypertension: A Scientific Statement From the American Heart Association.
    Circulation. 2024 Mar 7. doi: 10.1161/CIR.0000000000001197.
    

    >> Share

    
    December 2023
17. OSTERGAARD L, Olesen JB, Petersen JK, Nielsen LS, et al
    Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA(2)DS(2)-VASc 1: A Nationwide Study.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.066477.
    

    >> Share

    
    November 2023
18. GOTO S, Goto S
    Clinical Course of Isolated Distal Venous Thromboembolism in Patients With Active Cancer in a Nation With an Overall Low Risk of Thrombosis.
    Circulation. 2023;148:1677-1679.
    

    >> Share

    
    
19. HOSOKAWA K, Watanabe H, Taniguchi Y, Ikeda N, et al
    A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial.
    Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067528.
    

    >> Share

    
    March 2023
20. LASSEN MCH, Modin D, Skaarup KG, Johansen ND, et al
    Risk of Incident Thromboembolic and Ischemic Events After COVID-19 Vaccination Compared With SARS-CoV-2 Infection.
    Circulation. 2023;147:843-845.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share